Join to access to all OVN content. Join for Free
What is Your Value?: Defining and Driving MSL Value Demonstration
MSLs value demonstration patient-centricity internal collaboration tools and technology for MSLs strategies for undervalued MSLs

What is Your Value?: Defining and Driving MSL Value Demonstration


Share This Article


Summary

In this episode, Tom Caravela welcomes Cherie Hyder to discuss the critical topic of MSLs demonstrating VALUE. The conversation delves into defining value and effectively showcasing it to key stakeholders, including KOLs, with an emphasis on patient-centricity. The role of internal collaboration in enhancing value is examined, along with methods for measuring and communicating this value within organizations. They explore how tools and technology can aid MSLs in enhancing their perceived value and address common challenges faced in value demonstration. Strategies for MSLs who feel undervalued are shared, concluding with Cherie's final advice and closing remarks.

Key Points

  • Emphasizing both quantitative and qualitative metrics is essential for MSLs to effectively demonstrate their value within the organization.
  • Maintaining patient-centricity by understanding and communicating patient experiences and needs can significantly enhance the impact of an MSL's work.
  • Continuous self-investment in skills and capabilities is crucial for MSLs to adapt to changes and remain valuable in a rapidly evolving medical landscape.

Click for Source
MSLs value demonstration, patient-centricity, internal collaboration, tools and technology for MSLs, strategies for undervalued MSLs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
The Future of MSL Roles: Skills and Competencies for Tomorrow’s Challenges
Partner Avatar MSL Talk: Tom Caravela, Stephanie Otis

The Future of MSL Roles: Skills and Competencies for Tomorrow’s Challenges

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Explore OVN